Boehringer Ingelheim receives positive CHMP opinion for adalimumab biosimilar CYLTEZO®
Boehringer Ingelheim today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the Marketing Authorisation Application of Cyltezo® (adalimumab biosimilar), to treat multiple chronic inflammatory diseases in adults and children. The decision of the European Commission on the approval is expected in the fourth quarter of 2017.
“The recommendation by the CHMP for Cyltezo® is an important milestone for Boehringer Ingelheim, bringing us one step closer to providing our first biosimilar to healthcare providers and patients” said Ivan Blanarik, Senior Vice President and Head of Therapeutic Area Biosimilars at Boehringer Ingelheim. “Chronic inflammatory diseases can be incredibly debilitating and we are delighted that Cyltezo® has the potential to improve the lives of many of these patients. BI is committed to supporting the long-term potential of biosimilars, which we believe will be a key contributor to the future sustainability of healthcare systems around the world.”
The CHMP has recommended the approval of Cyltezo® for multiple chronic inflammatory diseases including, in adults:
- Moderate to severely active rheumatoid arthritis
- Psoriatic arthritis
- Moderate to severely active Crohn's disease
- Severe active ankylosing spondylitis
- Moderate to severely active ulcerative colitis
- Severe axial spondyloarthritis without radiographic evidence of AS
- Moderate to severe chronic plaque psoriasis
- Moderate to severe hidradenitis suppurativa
- Non-infectious intermediate, posterior and panuveitis.
The CHMP also recommends approval of Cyltezo® for the treatment of paediatric inflammatory diseases, including moderate to severe Crohn's disease (age six and older), severe chronic plaque psoriasis (age four and older), enthesitis-related arthritis (age six and older) and polyarticular juvenile idiopathic arthritis (age two and older).
The Marketing Authorisation Application (MAA) for Cyltezo® was based on a comprehensive data package supporting the biosimilarity of Cyltezo® to Humira® (adalimumab) based on analytical, pharmacological, non-clinical and clinical data, including results from the pivotal Phase III study VOLTAIRE®-RA, which demonstrated clinical equivalence of BI 695501 to the reference product in people with moderate to severely active rheumatoid arthritis. The pivotal phase III study met its primary endpoint showing no clinically meaningful difference in efficacy between BI 695501 and Humira® in terms of safety and immunogenicity.2
Cyltezo® was approved in the United States (U.S.) by the U.S. Food and Drug Administration (FDA) on August 25th 2017.3 Cyltezo® is not commercially available in the U.S. at this time. Boehringer Ingelheim is currently engaged in patent litigation with AbbVie in the U.S.
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.
For references and notes to editors, please visit: http://www.boehringer-ingelheim.com/press-release/positive-chmp-opinion-adalimumab-biosimilar-cyltezo
Media + PR
Dr. Julia Knebel
Phone: +49 6132 – 77 95614
Fax: +49 6132 – 77 6601
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Ipsen Receives Approval from European Commission for Xermelo® (Telotristat Ethyl) for the Treatment of Carcinoid Syndrome Diarrhea in Patients Inadequately Controlled by Somatostatin Analogue Therapy19.9.2017 19:00 | Tiedote
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced that the European Commission has approved Xermelo® (telotristat ethyl) 250 mg three times a day (tid) for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy. This approval allows for the marketing of Xermelo® (telotristat ethyl) in the above indication in all 28 member states of the European Union, Norway and Iceland. David Meek, Chief Executive Officer, Ipsen stated: “We are delighted to provide patients suffering from inadequately controlled carcinoid syndrome with a new treatment option in combination with a somatostatin analogue that demonstrates both efficacy and safety in particularly improving diarrhea, a most debilitating symptom. Xe
6th Annual World Patient Safety, Science & Technology Summit to Be Held in London, England19.9.2017 18:00 | Tiedote
The Patient Safety Movement Foundation (PSMF) announces that the 6th Annual World Patient Safety, Science & Technology Summit will take place in London on February 23-25, 2018. Rt. Hon. Jeremy Hunt MP, the Secretary of State for Health from England’s Department of Health, invited PSMF to hold its 6th annual Summit in London during his speech at the Summit in February of this year. This is the first time the Summit will be held outside of the United States. Over the years, the PSMF has taken an increasingly international scope to reach zero preventable patient deaths by 2020. They currently have over 30 Regional Chapters around the world and partnerships with global organizations such as the World Federation of Societies of Anaesthesiologists (WFSA), European Society of Anaesthesiology (ESA), Global Sepsis Alliance (GSA), the Taiwan Patient Safety Culture Club, Sistema Españo
Vertex Announces Upcoming Presentations of Data at 2017 North American Cystic Fibrosis Conference19.9.2017 17:50 | Tiedote
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that 11 abstracts from its cystic fibrosis (CF) research and development program will be presented at the annual North American Cystic Fibrosis Conference (NACFC) in Indianapolis, November 2 to 4, 2017. Previously announced data from the Phase 3 EVOLVE and EXPAND studies of the investigational tezacaftor/ivacaftor combination in people with CF ages 12 and older who have certain mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene will be presented for the first time. Additionally, data from the Phase 3 extension study of ORKAMBI® (lumacaftor/ivacaftor) in children with CF ages 6 to 11 who have two copies of the F508del mutation and real-world KALYDECO® (ivacaftor) data will be presented. The company also submitted an abstract for the late-breaking poster session with previously announced Phase 1
Biker Summer 2017 campaign: Last Chance to Win Great Prizes from Moto-tyres.co.uk19.9.2017 16:57 | Tiedote
Moto-tyres.co.uk wants to know: For the fifth year in a row, the online motorbike shop is asking bikers from ten European countries about their Biker Summer 2017 travel plans, favourite destinations and longest tours. For survey participants, Moto-tyres.co.uk and its sister shops in other European countries are raffling prizes to get every biker’s heart beating faster, including vouchers for new motorbike tyres, a GARMIN motorbike GPS navigation system, and a GoPro camera with helmet attachment. For more information and a link to the survey, go to: www.moto-tyres.co.uk/promotion-biker-summer-2017.html. The Biker Summer 2017 campaign is running until 30th September 2017 – so you still have time to join in and win top-quality equipment for your next bike tour. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170919006105/en/
Andersen Global Expands into Uruguay19.9.2017 16:30 | Tiedote
Andersen Global announces its expansion into Uruguay through a Collaboration Agreement with Fischer & Schickendantz, one of the country’s leading law firms. The addition of Fischer & Schickendantz continues Andersen Global’s expansion and robust presence within the Latin American region. The team is led by Managing Partner, Juan Federico Fischer. “The addition of Juan Federico and the individuals at Fischer & Schickendantz bring a new depth to our team and our business development efforts in South America, while allowing us to deliver additional services in the region,” said Andersen Tax CEO, Mark Vorsatz. “Uruguay is the next major step in our firm’s growth and is an excellent complement for Andersen Global. The ability to provide a full scope of services in Uruguay offers significant advantages, especially given their large cross border client base and Uruguay’s increase
Horizon Petroleum Enters into Definitive Agreements to Acquire Concessions in Poland19.9.2017 16:05 | Tiedote
Horizon Petroleum Ltd. (the “Company” or “Horizon”) (TSXV:HPL) is pleased to report that further to its press releases dated June 23, 2017, and July 26, 2017, it has entered into a series of definitive agreements (the “Agreements”) with Dublin-based San Leon Energy plc (“SLE”) regarding the purchase from wholly-owned subsidiaries of SLE and other SLE-controlled entities, of 100% interests in 2 oil & gas concessions in the Republic of Poland known as Cieszyn and Bielsko-Biala (the “Primary Concessions”), plus 100% working interests in 2 additional oil & gas concessions in Poland known as Prusice and Kotlarka, and another concession which is under application (together the “Secondary Concessions”). These concessions cover 3,030km2 and lie within the prolific Rotliegendes Basin and Carpathian Foldbelt, where Horizon intends to target undeveloped conventional natural gas discoveries. Gas infr
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme